hydroxylamine

Hydroxylamine, in the context of the clinical trial ChiCTR1900027116, is a translation error for **metaraminol** (known in Chinese as 间羟胺, which literally translates to meta-hydroxy-amine). Metaraminol is a potent sympathomimetic amine that acts as an agonist at alpha-1 adrenergic receptors, with some beta-adrenergic activity. It is used clinically as a vasopressor to treat acute hypotension and shock, including septic shock. In the Phase 4 trial conducted by the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), metaraminol (erroneously registered in English as hydroxylamine) was compared to noradrenaline (norepinephrine) to evaluate its efficacy and safety in patients with septic shock. True chemical hydroxylamine (NH2OH) is a toxic compound and is not used as a therapeutic agent in humans.